Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02314403 Background | Feb 2015 → Mar 2021 | chronic renal failure syndrome, impaired renal function disease | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314403 ↗ |
| Action | Deplete | “A T-Cell Depleting Agent” NCT02314403 ↗ |